Saniona ABFRA:30S +0.97%67 FCF Yield % is 10.13 as of Jun. 30, 2026. GuruFocus rates FRA:30S with a GF Score™ of 67/100 and a GF Value™ of €2.36 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Saniona AB ranks better than 97.03% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Saniona AB FCF Yield % Related Terms
Saniona AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Saniona AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:30S vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Saniona AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Saniona AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB (FRA:30S) has a FCF Yield % of 10.13 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #42 out of 1415 companies in the Biotechnology industry, placing it in the top 3%.
Is Saniona AB's FCF Yield % too high?
Saniona AB's current FCF Yield % is 10.13. Based on the distribution chart, Saniona AB ranks #42 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Saniona AB has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #42 out of 1415 companies for FCF Yield %. This places Saniona AB in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Saniona AB and its competitors. Saniona AB's current FCF Yield % is 10.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (FRA:30S) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.36, compared to a current price of €1.14 — trading 51.6% below its estimated fair value. The current FCF Yield % is 10.13. Saniona AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Saniona AB (FRA:30S), the current FCF Yield % is 10.13 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (FRA:30S) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of €1.14 is trading 51.6% below its estimated GF Value™ of €2.36.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for FRA:30S:
FCF Yield %: 10.13
GF Value™: €2.36 vs. price of €1.14 (51.6% below fair value)
No single metric tells the full story. See the FRA:30S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
67GF Score
Get the complete analysis for FRA:30S
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:30S has been successfully added to your 
